BTIG Says Rockwell Medical (RMTI) Launch of Calcitriol Inline with Views; Affirms at 'Buy'

September 22, 2016 10:21 AM EDT
Get Alerts RMTI Hot Sheet
Price: $5.48 -3.86%

Rating Summary:
    7 Buy, 2 Hold, 4 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade RMTI Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

BTIG affirms Rockwell Medical, Inc. (Nasdaq: RMTI) at Buy with a price target of $12 after the company provided an update on the commercial launch of Calcitriol, stating that stability data for completed finished product for commercial sale continues to remain within specification.

The firm said that timing for the launch was inline with its projection calling for late 2016/early 2017. The firm also noted:

  • Calcitriol launch has been delayed due to issues related to the specification for stability of one inactive ingredient by its third-party contract manufacturer (CMO).
  • Calcitriol provides a lower-cost alternative to Vitamin D for dialysis providers. Calcitriol is a generic vitamin D injection for the treatment of secondary hyperparathyroidism in dialysis patients. It is also the only generic vitamin D with clinical data which shows clinical equivalence in safety and efficacy to branded drugs, providing a lower-cost alternative for dialysis providers. We project Calcitriol peak sales of $48M in the US.

For an analyst ratings summary and ratings history on Rockwell Medical Technologies click here. For more ratings news on Rockwell Medical Technologies click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities


Add Your Comment